Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 14,435 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $81.54, for a total transaction of $1,177,029.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Gilead Sciences, Inc. (GILD) opened at $79.40 on Friday. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a market cap of $105,402.85, a PE ratio of 9.45, a P/E/G ratio of -1.85 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.70 earnings per share. analysts anticipate that Gilead Sciences, Inc. will post 6.24 EPS for the current year.
A number of institutional investors have recently made changes to their positions in the business. Welch Investments LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $144,000. Hanson & Doremus Investment Management boosted its stake in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares in the last quarter. Finally, Certified Advisory Corp acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $133,000. Hedge funds and other institutional investors own 75.71% of the company’s stock.
A number of brokerages have commented on GILD. Leerink Swann reiterated a “market perform” rating and issued a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target for the company in a research note on Monday. Mizuho reiterated a “buy” rating and issued a $95.00 price target (up previously from $83.00) on shares of Gilead Sciences in a research note on Monday, February 12th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research note on Thursday, February 8th. Finally, Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences presently has an average rating of “Buy” and an average price target of $86.92.
WARNING: This piece of content was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://stocknewstimes.com/2018/02/23/gilead-sciences-inc-gild-evp-gregg-h-alton-sells-14435-shares.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.